Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 295.00 0.00 07:43:00
Bid Price Offer Price High Price Low Price Open Price
280.00 310.00 295.00 295.00 295.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.16 -6.95 -0.27 82
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 295.00 GBX

Arecor Therapeutics (AREC) Latest News

More Arecor Therapeutics News
Arecor Therapeutics Investors    Arecor Therapeutics Takeover Rumours

Arecor Therapeutics (AREC) Discussions and Chat

Arecor Therapeutics Forums and Chat

Date Time Title Posts
09/8/202210:58Arecor205

Add a New Thread

Arecor Therapeutics (AREC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-08-15 16:18:05298.005,00014,900.00O
2022-08-15 16:12:35300.002,5007,500.00O
2022-08-15 15:25:56282.001,0352,918.70O
View all Arecor Therapeutics trades in real-time

Arecor Therapeutics (AREC) Top Chat Posts

DateSubject
16/8/2022
09:20
Arecor Therapeutics Daily Update: Arecor Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 295p.
Arecor Therapeutics Plc has a 4 week average price of 295p and a 12 week average price of 295p.
The 1 year high share price is 460p while the 1 year low share price is currently 228p.
There are currently 27,835,024 shares in issue and the average daily traded volume is 4,797 shares. The market capitalisation of Arecor Therapeutics Plc is £82,113,320.80.
02/8/2022
12:11
timbo003: see new Trinity Delta research note on AREC (issued yesterday) https://www.trinitydelta.org/research-notes/acquisition-of-tetris-pharma-and-6m-equity-raise/
01/8/2022
16:13
stupidboypike: Glad you got some timbo, I've been looking at the deal for a while now and I do think on balance it looks very good news. I'm already very overweight in Arecor, so I haven't taken any in this round, although I think 300p with EIS relief is a very good price. Best regards SBP
01/8/2022
15:59
timbo003: I managed to pick up a few (EIS) shares in the Book build, but was scaled back by 64%, however given that the share register for Arecor reads like a who's who in the VCT world and VCTs had another bumper fund raising year last tax year, I was expecting a larger scale back than that.
01/8/2022
09:24
stupidboypike: Interestingly I remember hearing that the glucagon development had been put on hold as another company was making good progress with it. I guess that is this one. This could be a very smart move by Arecor. Not thrilled about the dilution, but if they have got it right that will be a very sensible price to pay I think. I also like the fact that half the payment is not due until/unless the acquired company becomes profitable. Best regards SBP
01/8/2022
07:55
18bt: First reaction: looks highly complementary. However placing is c10% increase in share capital, but they are targeting a v small discount albeit to a share price which has reduced a lot in last couple of weeks. Potentially large deferred consideration which will have to be watched.
27/4/2022
07:46
alloa2003: This has huge long term potential and the steady as we go approach should avoid huge volatility in the share price.
06/4/2022
08:45
stupidboypike: sn, I agree, in fact we can see what happened in September when some people did want to buy in quantity, the share price doubled in a very short period. I have a decent holding of Arecor, built up over many years ( I held from the formation of the company), and I don't intend selling any until the value has properly started to come out. That in my opinion is many times the current market cap. Best regards SBP
31/3/2022
23:39
sharesoc: In case you missed our webinar with Arecor Therapeutics (AREC), the recording can be found on our YouTube channel: hTTps://youtu.be/DW_9-yNzVaY
23/3/2022
07:38
alloa2003: Nice progress:- ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company's extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278. Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. This recently granted US patent, the first within the Group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress." Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. Arecor's strategy is to generate a fortress of both narrow and broad interrelated IP rights that cover the features of these products. US11278624 is the first granted US patent within the Group's comprehensive insulin IP strategy.
02/3/2022
21:24
sharesoc: We are hosting a webinar with Arecor Therapeutics plc (AREC) on 15 March 2022, which may be of interest to current shareholders or potential investors. Sarah Howell (Chief Executive Officer) will be presenting. You can register here: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-arecor-therapeutics-plc-arec15-march-2022/
Arecor Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AREC
Arecor The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220816 13:16:01